Letter | Published:

Cannabinoids control spasticity and tremor in a multiple sclerosis model

Nature volume 404, pages 8487 (02 March 2000) | Download Citation



Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an autoimmune model of multiple sclerosis1. Although both these diseases are typified by relapsing-remitting paralytic episodes, after CREAE induction by sensitization to myelin antigens1 Biozzi ABH mice also develop spasticity and tremor. These symptoms also occur during multiple sclerosis and are difficult to control. This has prompted some patients to find alternative medicines, and to perceive benefit from cannabis use2. Although this benefit has been backed up by small clinical studies, mainly with non-quantifiable outcomes3,4,5,6,7, the value of cannabis use in multiple sclerosis remains anecdotal. Here we show that cannabinoid (CB) receptor agonism using R(+)-WIN 55,212, Δ 9-tetrahydrocannabinol, methanandamide and JWH-133 (ref. 8) quantitatively ameliorated both tremor and spasticity in diseased mice. The exacerbation of these signs after antagonism of the CB1 and CB2 receptors, notably the CB1 receptor, using SR141716A and SR144528 (ref. 8) indicate that the endogenous cannabinoid system may be tonically active in the control of tremor and spasticity. This provides a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis2, and provides a means of evaluating more selective cannabinoids in the future.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J. Neuroimmunol. 28, 261 –270 (1990).

  2. 2.

    , , , & The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38, 44–48 (1997).

  3. 3.

    Cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis. 5, 534– 551 (1998).

  4. 4.

    & Treatment of human spasticity with Δ9-tetrahydrocannabinol. J. Clin. Pharmacol. 21 (suppl.), 413–416 ( 1981).

  5. 5.

    Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. 13, 669–671 ( 1983).

  6. 6.

    , , , & Δ9-THC in the treatment of spasticity associated with multiple sclerosis. Adv. Alcohol Substance Abuse 7, 39– 50 (1987).

  7. 7.

    , & Nabilone in the treatment of multiple sclerosis. Lancet 345, 579 (1995).

  8. 8.

    Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6, 635–664 ( 1999).

  9. 9.

    , , , & Δ9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23, 73–81 (1989).

  10. 10.

    et al. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28, 209 –214 (1994).

  11. 11.

    & Electrophysiological studies with the spastic mutant mouse. Brain Res. 234, 299–308 (1982).

  12. 12.

    Hereditary spasticity in mice. J. Heredity 52, 241–243 (1961).

  13. 13.

    Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Therapeut. 74, 129–180 ( 1997).

  14. 14.

    & The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. 5, 417–431 (1998).

  15. 15.

    , , , & SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334, R1–R2 (1997).

  16. 16.

    et al. SR144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol Exp. Ther. 288, 582–589 (1999).

  17. 17.

    , , & Control of pain initiation by endogenous cannabinoids. Nature 394, 277–281 (1998).

  18. 18.

    et al. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nature Neurosci. 2, 358 –363 (1999).

  19. 19.

    et al. 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ 9-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 7, 2905–2914 (1999).

  20. 20.

    Trends in the pathophysiology and pharmacotherapy of spasticity. J. Neurol. 238, 131–139 (1991).

Download references


The authors would like to thank the Multiple Sclerosis Society of Great Britain and Northern Ireland, the Medical Research Council, the National Institute on Drug Abuse and the Wellcome Trust for their financial support.

Author information


  1. *Neuroinflammation Group, Department of Neurochemistry, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ and the Institute of Ophthalmology, UCL, London EC1V 9EL, UK

    • David Baker
    • , Gareth Pryce
    •  & J. Ludovic Croxford
  2. †The Medical Research Council Human Movement and Balance Unit, National Hospital for Neurology and Neurosurgery , Queen Square, London, WC1N 3BG, UK

    • Peter Brown
  3. ‡Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill , Aberdeen AB25 2ZD, UK

    • Roger G. Pertwee
  4. §Department of Chemistry, Clemson University, Clemson, South Carolina 29634-1905 , USA

    • John W. Huffman
  5. Multiple Sclerosis Society of Great Britain and Northern Ireland , 25 Effie Road, London SW6 1EE, UK


  1. Search for David Baker in:

  2. Search for Gareth Pryce in:

  3. Search for J. Ludovic Croxford in:

  4. Search for Peter Brown in:

  5. Search for Roger G. Pertwee in:

  6. Search for John W. Huffman in:

  7. Search for Lorna Layward in:

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.